

Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications

Marie-Lise Jaffrain-Rea^{1,2,3}, Mariolina Angelini¹, Donatella Gargano¹, Maria A Tichomirowa⁴, Adrian F Daly⁴, Jean-François Vanbellingen⁵, Emanuela D'Innocenzo¹, Anne Barlier⁶, Felice Giangaspero^{2,7}, Vincenzo Esposito², Luca Ventura⁸, Antonietta Arcella², Marilyn Theodoropoulou⁹, Luciana A Naves¹⁰, Carmen Fajardo¹¹, Sabina Zacharieva¹², Vincent Rohmer¹³, Thierry Brue⁶, Alberto Gulino⁷, Giampaolo Cantore², Edoardo Alesse¹ and Albert Beckers⁴

¹Department of Experimental Medicine, University of L'Aquila, via Vetoio, Coppito 2, 67100 L'Aquila, Italy

²Neuromed Institute, Istituto di Ricovero e di Ricerca a Carattere Scientifico, Via Atinense 18, 86077 Pozzilli, Italy

³Fondazione 'Carlo Ferri' per la prevenzione e la cura dei tumori, via Edmondo Riva 42, 00015 Monterotondo, Italy

⁴Departments of Endocrinology and ⁵Molecular Genetics, Centre Hospitalier Universitaire de Liège, Université de Liège, 4000 Liège, Belgium

⁶Department of Endocrinology, Hôpital de la Timone, Centre de Référence des maladies rares d'origine hypophysaire, Assistance Publique-Hôpitaux de Marseille, and Centre de Recherche en Neurobiologie - Neurophysiologie de Marseille (CRN2M), Unité Mixte de Recherche 6231, Université de la Méditerranée - Université Paul Cézanne - CNRS, 13284 Marseille, France

⁷Department of Experimental Medicine and Pathology, University of Rome 'La Sapienza', Viale dell'Università, 00161 Rome, Italy

⁸Pathology, San Salvatore Hospital, Coppito, 67100 L'Aquila, Italy

⁹Max Planck Institute of Psychiatry, 80804 Munich, Germany

¹⁰Endocrinology Unit, Faculty of Medicine, University of Brasilia, 70910-900 Brasilia, Brazil

¹¹Department of Endocrinology, Hospital Universitario de La Ribera, 46600 Alzira, Spain

¹²Department of Endocrinology, Sofia University, 1303 Sofia, Bulgaria

¹³Endocrinology, Centre Hospitalier Universitaire de Angers, 49033 Angers, France

(Correspondence should be addressed to M-L Jaffrain-Rea; Email: jaffrain.ml@libero.it)

Abstract

Germline mutations of the aryl hydrocarbon receptor (AHR)-interacting protein (*AIP*) gene confer a predisposition to pituitary adenomas (PA), usually in the setting of familial isolated PA. To provide further insights into the possible role of *AIP* in pituitary tumour pathogenesis, the expression of *AIP* and AHR was determined by real-time RT-PCR and/or immunohistochemistry (IHC) in a large series of PA ($n=103$), including 17 with *AIP* mutations (*AIP*^{mut}). Variable levels of *AIP* and AHR transcripts were detected in all PA, with a low AHR expression ($P<0.0001$ versus *AIP*). Cytoplasmic *AIP* and AHR were detected by IHC in 84.0 and 38.6% of PA respectively, and significantly correlated with each other ($P=0.006$). Nuclear AHR was detected in a minority of PA (19.7%). The highest *AIP* expression was observed in somatotrophinomas and non-secreting (NS) PA, and multivariate analysis in somatotrophinomas showed a significantly lower *AIP* immunostaining in invasive versus non-invasive cases ($P=0.019$). *AIP* expression was commonly low in other secreting PA. *AIP* immunostaining was abolished in a minority of *AIP*^{mut} PA, with a frequent loss of cytoplasmic AHR and no evidence of nuclear AHR. In contrast, *AIP* overexpression in a subset of NS PA could be accompanied by nuclear AHR immunopositivity. We conclude that down-regulation of *AIP* and AHR may be involved in the aggressiveness of somatotrophinomas. Overall, IHC is a poorly sensitive tool for the screening of *AIP* mutations. Data obtained on AHR expression suggest that AHR signalling may be differentially affected according to PA phenotype.

Endocrine-Related Cancer (2009) 16 1029–1043

Introduction

Germline mutations of the aryl hydrocarbon receptor (AHR)-interacting protein (*AIP*) gene confer a predisposition to pituitary adenomas (PA; Vierimaa et al. 2006), usually in the setting of familial isolated PA (FIPA; Daly et al. 2006, 2007, Beckers & Daly 2007). Because mutations are likely to be inactivating and associated with tumour loss of heterozygosity (LOH), *AIP* is viewed as a new pituitary tumour suppressor gene in 11q13 (Vierimaa et al. 2006). Most PA associated with *AIP* mutations (*AIP*^{mut}) are somatotrophinomas or prolactinomas – although non-secreting (NS) adenomas occur occasionally (Buchbinder et al. 2008). The prevalence of *AIP* mutations in FIPA is 15% overall, but reaches 50% in FIPA kindreds with homogeneous somatotrophinomas (Vierimaa et al. 2006, Daly et al. 2007). *AIP*^{mut} PA occur earlier than their sporadic counterpart and are usually more aggressive (Beckers & Daly 2007, Daly et al. 2007). Immunohistochemistry (IHC) has shown *AIP* to be expressed by PA, with loss of *AIP* staining in *AIP*^{mut} tumours being variably appreciated (Vierimaa et al. 2006, Georgitsi et al. 2007, Leontiou et al. 2008). As such, the clinical application of IHC for *AIP* as a screening tool remains controversial. Germline *AIP* mutations are very rare in patients with sporadic PA, although they can be encountered in young acromegalics (Barlier et al. 2007, Cazabat et al. 2007, Iwata et al. 2007, Georgitsi et al. 2008a). In addition, although variations in *AIP* expression among sporadic PA have been recently reported according to their functional phenotype (Leontiou et al. 2008), their potential relationship with tumour-evolutionary features has not been investigated. Thus, the possible role of *AIP* in PA pathogenesis independently of germline mutations is unknown.

The best characterized function of *AIP* is to stabilize the AHR, or dioxin receptor, in a cytoplasmic core complex involving *AIP*, AHR and the heat shock protein Hsp90. Upon activation, AHR moves to the nucleus and heterodimerizes with the Ah receptor nuclear translocator (ARNT) to exert direct transcriptional effects (Petruilis & Perdeu 2002). AHR is widely expressed in endocrine tissues, and dioxin-related compounds are endocrine disruptors (Pitt et al. 2000, Nishimura et al. 2002, Pocar et al. 2005). *In vitro* exposure to 2,3,7,8 tetrachlorodibenzo-*p*-dioxin induces GH and prolactin (PRL) secretion from rainbow trout pituitary cells, in part through AHR-mediated transcriptional effects (Elango et al. 2006). *AIP* generally enhances AHR response to exogenous ligands by increasing its cytoplasmic levels, but nuclear localization of non-ligand-bound AHR can be

observed in the absence of *AIP* (LaPres et al. 2000). This may be relevant to *AIP*-related tumorigenesis, since endogenous functions of AHR are being increasingly recognized (Barouki et al. 2007, Nguyen & Bradfield 2008). AHR exerts complex modulatory effects on cell cycle regulation and apoptosis (Marlowe & Puga 2005), and genetic models have clearly underscored its involvement in normal ontogeny and in tumorigenesis (Gasiewicz et al. 2008). Dioxin is carcinogenic (Popp et al. 2006), and AHR can be overexpressed in human tumours (Harper et al. 2006, Schlezinger et al. 2006). Yet, the effects of dioxin exposure on the incidence of pituitary tumours remain uncertain (Pesatori et al. 2008), and the expression of AHR in the normal human pituitary and in PA has not been reported to date.

We wished to further characterize *AIP* expression and assess AHR expression and cellular localization in a representative series of PA. We also aimed to further characterize *AIP*^{mut} PA in order to provide new insights into their pathogenesis and possibly help identify patients who could benefit from *AIP* mutational screening.

Material and methods

Patients and samples

A series of 103 PA have been studied for *AIP* and AHR expression by real-time RT-PCR ($n=66$) and/or IHC ($n=94$). There were 46 GH-, 22 PRL-, 7 ACTH-, 2 TSH-secreting and 26 NS adenomas respectively. Unselected sporadic adenomas were operated on for medical reasons at the Neuromed Institute (Italy). Seventeen FIPA samples were collected in 14 FIPA patients who came from eight international centres (Italy, Belgium, France, Brazil, Spain and Bulgaria), out of which 10 PA were operated on in 8 patients with a germline *AIP* mutation. The study was approved by local ethical committees. Clinical, biological and neuroradiological data, as well as intra-operative findings and pre-operative pharmacological treatment, were systematically recorded. Invasiveness was defined according to pre-operative neuroradiological imaging and intra-operative findings, including macroscopic evidence of dural infiltration. Tumour phenotype was defined on the basis of pre-operative endocrine evaluation and immunohistochemical characterization of hormone secretion. This latter was available in all but two cases and performed with the commercial anti-PRL, anti-GH, anti-FSH, anti-LH, anti-ACTH and anti-TSH antibodies in use in the participating centres (in Italy, polyclonal antibodies from Orthodiagnostic Systems, Raritan, NJ, USA).

Cell proliferation was evaluated in 77 PA by Ki-67 immunostaining with the monoclonal MIB-1 antibody (DBA Italia srl, Milan, Italy), as previously described (Jaffrain-Rea *et al.* 2002). Tumours showing microscopic evidence of contamination by normal pituitary fragments were considered for immunohistochemical studies only. In addition, normal human pituitary glands were collected at autopsy in four patients who died from non-endocrine diseases and divided into frozen and formalin-fixed paraffin-embedded fragments, as previously described (Fratricci *et al.* 2007).

Molecular and genetic analysis

Methodological details on RT-PCR and real-time RT-PCR protocols are provided in the Supplementary Materials and methods, which can be viewed online at <http://erc.endocrinology-journals.org/supplemental/>. Briefly, after preliminary, RT-PCR experiments allowed the exclusion of tumour samples with potential contamination with normal pituitary cells according to cell-specific transcription factors' criteria and revealed an almost universal *AIP* and *AHR* gene expression; *AIP* and *AHR* transcripts were quantified by real-time RT-PCR based on a Taqman methodology and corrected for β -actin expression. Leukocyte genomic *AIP* sequencing (gDNA) was performed in 28 patients, as previously described (Daly *et al.* 2007). Searches for somatic mutations, or LOH in *AIP*^{mut} tumours, were performed by direct sequencing of tumour cDNA and/or DNA (tDNA) in 35 and 6 cases respectively. Procedures for *AIP* cDNA sequencing are described in the electronic Supplementary Materials and methods. Overall, the *AIP* gene status could be determined in 67 cases. Wherever new changes in *AIP* sequencing were identified, *AIP* variations were considered as *AIP* mutations for statistical purposes and their potential biological significance further analysed in the Supplementary Materials and methods and in the Discussion section.

Immunohistochemistry

Tissue sections were dewaxed in xylene and rehydrated through a descending ethanol series, and antigen retrieval was performed by microwave boiling at 850 W in citrate buffer 0.1 M, pH 6.0. Mouse monoclonal antibodies directed against *AIP* (clone 35-2) and *AHR* (clone RPT9, referred to as 'N-mAb') were purchased from Novus (Novus Biologicals LLC, Littleton, CO, USA) and both used at a 1:500 dilution, in 94 and 83 PA respectively. A polyclonal rabbit anti-*AHR* antibody was also used




Figure 1 *AIP* and *AHR* gene expression in pituitary adenomas according to tumour phenotype box plots representing *AIP*/ β -actin and *AHR*/ β -actin mRNA ratios in all prolactinomas (PRL), somatotrophinomas (GH), non-secreting adenomas (NS), corticotrophinomas (ACTH), thyrotroph adenomas (TSH) and in normal pituitary samples (NP) are shown in panels A and B respectively (note the different scales used).

in 61 PA (17 PRL-, 21 GH-, 3 ACTH-secreting and 20 NS respectively) at a 1:50 dilution (sc-5579, referred to as 'C-pAb', Santa Cruz Biotechnology, Santa Cruz, CA, USA). This antibody proved to be more sensitive than the N-mAb in the detection of nuclear *AHR* in positive control sections (human invasive breast cancer samples and rat liver), and cytoplasmic background could be reduced by introducing a further blocking step with 5% milk in PBS. IHC was performed with a multilink biotinylated antibody and the avidin-biotin peroxidase system according to the manufacturer's instructions (LSAB+ kit, DAKO Cytomation, Milan, Italy). Negative controls were performed omitting the primary antibody. Topographical localization of *AIP*-expressing cells in normal pituitaries was performed

Table 1 Aryl hydrocarbon receptor-interacting protein (AIP) expression in the whole series of pituitary adenomas (PA) according to patients and tumours characteristics

Phenotype	All	Age (years)		P	Pre-operative treatment			Invasiveness			SSE		
		<30	≥30		Treated	Untreated	P	Invasive	Non-Invasive	P	Present	Absent	P
All PA													
<i>AIP/β-actin</i> mRNA (66)	0.8±0.9	0.3±0.4	0.9±1.0	0.015		N/A	–	0.5±0.7	1.0±1.0	0.0197	0.7±0.5	0.9±1.1	NS
AIP staining (94)	37/94 39.4%	11/32 34.4%	26/62 41.9%	NS			–	14/52 26.4%	22/41 53.6%	0.0090	20/63 31.7%	17/31 54.8%	0.031
GH-secreting													
<i>AIP/β-actin</i> mRNA (20)	0.9±0.9	0.5±0.6	1.0±1.0	NS	0.8±0.9	1.0±1.0	NS	0.3±0.2	1.1±1.0	0.039	0.8±0.6	0.9±1.1	NS
AIP staining (44)	23/44 52.3%	9/19 47.4%	14/25 56.0%	NS	12/19 63.1%	11/25 41.7%	NS	6/22 27.3%	17/22 77.3%	0.0009	8/25 32.0%	15/19 77.7%	0.002
PRL-secreting													
<i>AIP/β-actin</i> mRNA (12)	0.5±0.5	0.1±0.1	0.6±0.5	NS	0.3±0.3	0.6±0.7	NS	0.4±0.3	1.0±0.9	NS	0.5±0.5	–	NS
AIP staining (21)	3/21 14.3%	1/8 12.5%	2/13 15.4%	NS	1/7 14.3%	2/14 14.3%	NS	3/15 20.0%	0/6 –	NS	3/16 18.7%	0/5 –	NS
Non-secreting													
<i>AIP/β-actin</i> mRNA (25)	1.0±1.3	0.3±0.1	1.0±1.3	NS		N/A	–	0.7±1.0	1.0±1.0	NS	1.0±1.03	0.6	–
AIP staining (21)	9/21 42.8%	1/3 33.3%	8/17 47.0%	NS			–	5/14 35.7%	3/6 50.0%	NS	9/19 47.4%	0/1 –	NS
ACTH-secreting													
<i>AIP/β-actin</i> mRNA (7)	0.7±0.3	0.4	0.7±0.3	–		N/A	–	0.4	0.7±0.3	–	0.4±0.1	0.8±0.3	NS
AIP staining (6)	1/6 16.7%	0/1 –	1/5 20.0%	–			–	0/1 –	1/5 20.0%	–	0/2 –	1/4 25.0%	NS
TSH-secreting													
<i>AIP/β-actin</i> mRNA (2)	0.2±0.1	0.3	0.1	–	0.2±0.1	–	–	–	0.2±0.1	–	–	0.2±0.1	–
AIP staining (2)	0/2 –	0/1 –	0/1 –	–	0/2 –	–	–	–	0/2 –	–	–	0/2 –	–

For raw data, the number of studied cases is indicated within brackets. The *AIP/β-actin* ratio was defined according to real-time RT-PCR experiments. AIP staining refers to significant AIP immunostaining (+ diffuse, moderate and ++ diffuse, strong) – as compared with very low or absent staining. SSE, suprasellar extension; N/A, not applicable; NS, non-significant data.




Figure 2 AIP and AHR immunostaining in pituitary adenomas (PA), excluding AIP^{mut} PA. Shown are representative examples of AIP and AHR immunostaining in different pituitary adenomas (PA), excluding AIP^{mut} PA. For each image, the PA endocrine phenotype is indicated in the upper right corner, the corresponding antibody in the bottom left corner and magnification in the bottom right corner respectively. AIP immunostaining was quoted ++ in a somatotrophinoma, + in a non-secreting PA and +/- in a prolactinoma (A, B and C respectively). An example of microprolactinoma displaying AIP and AHR down-regulation (quoted +/-) as compared with the adjacent normal pituitary (indicated as NP) is shown in D and E respectively; nuclear AHR staining in this case was observed in the normal pituitary, but not in adenoma cells (F). Most PA had no or weak AHR immunoreactivity (G and H respectively), a few cases displaying nuclear immunostaining, including a non-secreting FIPA without AIP mutation (I).

using pre-diluted mouse mAbs for pituitary hormones (DAKO Cytomation). Semi-quantitative analysis of cytoplasmic AIP and AHR immunostaining was performed at 20 \times and 40 \times magnifications and semiquantitatively scored as follows: – (negative); +/- (weak immunostaining and/or scattered positive cells); + (diffuse, moderate immunostaining); ++ (diffuse, strong immunostaining). In the presence of heterogeneous staining, the areas obtaining the highest score were considered for statistical purposes. Nuclear staining for AHR (C-pAb) was further evaluated at high magnification (100 \times) in all cases. A double step immunohistochemical study was also performed as previously described (Fratticci *et al.* 2007) to first detect cytoplasmic AIP or the pituitary hormones GH, PRL, ACTH and FSH respectively using 3-3'-diaminobenzidine (DAB) as a chromogen, followed by a second step for the detection of nuclear AHR (C-pAb) using Novored as a chromogen (Vector, DBA Italia), introducing a further blocking step with

milk as indicated hitherto. Photographs of slides were taken using a Zeiss Axioplan 2 microscope and a Leica DFC 320 digital camera.

Statistical analysis

All data are expressed in mean \pm s.d. and statistical analyses were performed using Statview 5.01 software for PC (SAS Institute, Cary, NC, USA). Continuous values were analysed by non-parametric analysis, using Mann–Whitney and Kruskal–Wallis test for 2 and ≥ 3 group comparisons respectively and the Spearman test for correlation studies. Distribution of nominal values was compared by the χ^2 -test, logistic regression being used for multivariate analysis. For logistic regression and analysis of subgroups, the immunostaining scores for cytoplasmic AIP and AHR were transformed into binary parameters as follows: significant (scores + and ++) versus low (– and +/-) AIP immunostaining; and

Table 2 Characteristics of pituitary adenomas (PA) with *AIP* mutations and immunohistochemistry (IHC) for aryl hydrocarbon receptor (AHR)-interacting protein (AIP) and AHR

Patients surgery ^a	<i>AIP</i> mutation	Country	Sex	Age (years)	Symptoms ^b	Tumour ^c	Hormone values at diagnosis (ng/ml)	Pre-op treatment	Pre-op hormone values (ng/ml)	Pituitary hormones IHC	AIP IHC ^d	AHR IHC ^e
Fam 1 ^(i,ii) Fam 1A TC	R304X	Italy	F	19	Amenorrhoea–galactorrhoea, visual loss, bitemporal haemianopsia, weight gain and hydrocephalus requiring emergency surgery for ventricular derivation (VD)	Giant-SSE (52 mm), Inv+ (CS)	PRL 99, Post-VD, GH 15.8, IGF-I 420, PRL 32	OCT up to 200 µg t.i.d. CAB 0.5 mg ×2/w	PRL 9.1, GH 16.0, IGF 900	GH, FSH (±), Ki-67, 0.5%	+/- (scattered cells +)	C – N –
Fam 1B 1 st TS	R304X	Italy	F	21	Amenorrhoea, weight gain, mild acromegaly, DH 164 cm and headache	Giant-SSE (41 mm), Inv+ (CS)	GH 33, IGF-I 630, PRL 5	None	See values at diagnosis	GH, PRL (±), Ki-67, 6.0%	+/-	C – N ND
2 ^o TS	R304X	Italy	F	22	Evolutionary disease and pharmacological resistance	Ma-SSE (27 mm), Inv+ (CS)	<i>Post-TS1</i> GH 4.0, IGF-I 400, PRL 7.2	LAN 30 mg /14 d. CAB 0.5 mg ×2/w.	GH 5.8 IGF-I 598 PRL 1.3	GH, FSH, LH (±), Ki-67, 2.7%	+/-	C – N ND
Fam 1C TS	R304X	Italy	M	8	Incipient gigantism	Ma-IS (12 mm), Inv –	GH 48.2, IGF-I 1070, PRL 11.8	OCT-LAR 10 mg/28 d.	GH 65.9 IGF-I 1294 PRL 21.9	GH, Ki-67, 5.0%	+/- (scattered cells +)	C – N –
Fam 2 ⁽ⁱ⁾ Fam 2A TS	Q285fs17X	Italy	M	21	Gigantism – DH 208 cm, headache and visual fields' defects	Ma-SSE (28 mm), Inv+	GH > 30.0, PRL 7.4, IGF-I N/A	None	See values at diagnosis	GH, PRL (±), Ki-67, 0.7%	+/-	C – N –
Fam 2B 1 st TS	Q285fs17X	Italy	M	33	Acromegaly – DH 185 cm	Ma-SSE (30 mm), Inv+ (CS)	GH 74.0, IGF-I 664, PRL 35.4	OCT-LAR 20 mg/28 d.	GH 3.5, IGF-I 414, PRL 4.4	GH, PRL, FSH (±), Ki-67, 0%	+/- (large areas –)	C – N –
2 nd TS	Q285fs17X	Italy	M	34	Evolutionary acromegaly	Ma-IS (15 mm), Inv+ (CS)	GH 6.0, IGF-I 540, PRL 7.0	OCT-LAR 10 mg/28 d.	GH 19.6, IGF-I 449, PRL 6.7	GH, PRL (±), Ki-67, 0%	–	C –
Fam 3 ⁽ⁱ⁾ Fam 3A TS	K241E	Belgium	F	53	Visual loss and bitemporal haemianopsia.	Ma-SSE (30 mm), Inv+	PRL 41, IGF-I 50	None	See values at diagnosis	FSH, LH	+	C – N –
Fam 3B TS	K241E	Belgium	M	53	Visual loss	Ma-SSE (34 mm), Inv+ (CS)	PRL 2333, GH 0.2, IGF-I 100	CAB 0.5 mg ×2/w.	PRL 12.5, GH 0.2	PRL	–	C – N ND

Table 2 continued

Patients surgery ^a	AIP mutation	Country	Sex	Age (years)	Symptoms ^b	Tumour ^c	Hormone values at diagnosis (ng/ml)	Pre-op treatment	Pre-op hormone values (ng/ml)	Pituitary hormones IHC	AIP IHC ^d	AHR IHC ^e
Fam 4 ⁽ⁱⁱⁱ⁾ TS	E174fs21X	Brazil	M	17	Gigantism, DH 193 cm, headache and visual fields' defect	Giant-SSE (46 mm), Inv+ (CS)	GH 51, IGF-I 778, PRL 50	None	See values at diagnosis	GH, PRL, Ki-67, 0%	Het +, +/-	C+/- N -
Spor 1 TS	V195A	Brazil	M	12	Visual loss and pre- puberal, post-oper- ative resistance to dopamine-agonists	Giant-SSE (40 mm) Inv+ (CS)	PRL 10 561, GH 0.06, IGF-1 147	None	See values at diagnosis	PRL, Ki-67, 0%	+	C- N ND
Spor 2 TS	A277P	Italy	M	12	Incipient gigantism and visual defect	Ma-SSE (27 mm), Inv+ (CS)	GH 13.6, IGF-I 530, PRL 52.5	None	See values at diagnosis	GH, PRL, Ki- 67, 15.0%	+/-	C- N-
Spor 3 TS	IVS3 c.468+ 16G>T	Italy	F	15	Oligomenorrhoea, visual field defects and then pituitary apoplexy	Ma-SSE (20 mm), Inv+ (CS)	N/A	None	N/A	GH, Ki-67, 0.5%	- (in part necrotic)	ND
Spor 4 TS	IVS3 c.468+ 15C>T	Spain (Ecuador)	F	17	Acromegaly, tall sta- ture, headache and menstrual distur- bance	Ma-IS (13 mm), Inv-	GH 54.8, IGF-I 635, PRL ↑	LAN-60 mg i.m. /28 d.	N/A	GH, PRL FSH, LH, ACTH (±)	Het +/-, -	C+/- N ND
Spor 5	Q82fsX7	Bulgaria	M	15	Gigantism, headache and hydrocephalus	Giant-SSE (60 mm), Inv+	N/A	None (RxT)	GH 42.3, IGF-I ↑, PRL 60	GH	-	C- N ND
Spor 6 TS	R128H	Belgium (Morocco)	M	27	Acromegaly	Ma-SSE (20 mm), Inv-	GH 58.7, IGF-I 909, PRL N/A	OCT 100 µg t.i.d. CAB 0.5 mg ×2/w	IGF-I 1090	GH	Het + +/+	ND
Spor 7 TS	IVS2 c.279+ 23C>T	Italy	F	43	Secondary amenor- rhoea, headache and transient visual defects	Ma-SSE (18 mm), Inv-	PRL 30, GH 0.2, IGF-I 152	None	See values at diagnosis	PRL, GH (±), Ki-67, 3.0%	+/-	C- N-
Spor 8 ^(T) TS	R304X	Italy	F	17	Visual defects, headache, sec- ondary amenor- rhoea and DH 171 cm	Ma-SSE, Inv-	GH 9.0, IGF-I 905, PRL 57	None	See values at diagnosis	GH, Ki-67, 3.0%	+/-	ND

^{a(i)}Previously reported in *Daly et al. (2007)*, ⁽ⁱⁱ⁾clinical details on Fam1 A and B previously reported in *Ferretti et al. (2001)*, ⁽ⁱⁱⁱ⁾previously reported in details in *Naves et al. (2007)*, (T) only tumour available.

^bDH, definitive height.

^cMa, macroadenoma; SSE, suprasellar extension; maximal tumour diameter within brackets; Inv-, non-invasive; Inv+, invasive; CS, cavernous sinus.

^dAIP staining with semi-quantitative score. ++ strong, diffuse; + moderate, diffuse; +/- weak or scattered positive cells; - negative.

^eAHR staining; C, cytoplasmic staining with an N-terminal monoclonal antibody; N, nuclear staining with a C-terminal polyclonal antibody respectively; ND, not done (unavailable material).

Table 3 Characteristics of somatotrophinomas and relationship with the presence of aryl hydrocarbon receptor-interacting protein (AIP) mutations

	Group A	Group B	P
Patients			
Age	18.7 ± 6.6	40.1 ± 12.5	<i>P</i> < 0.0001
Sex	7M/5F	13M/17F	NS
Tumours			
Suprasellar extension	10/14 (71.4%)	16/32 (50.0%)	NS
Invasive	10/14 (71.4%)	12/32 (37.5%)	$\chi^2 = 4.49$, <i>P</i> = 0.034
Ki-67, > 3.0%	5/11 (45.4%)	6/29 (20.7%)	NS
Pre-operative treatment	7/14 (50.0%)	13/32 (40.6%)	NS
AIP expression			
<i>AIP/β-actin</i> mRNA (<i>n</i>)	0.18 ± 0.05 (4)	1.05 ± 0.98 (16)	<i>P</i> = 0.072
AIP score (–; +/–; ++; +++)	2;8;3;1	1;10;15;4	NS
Low AIP score (+/–, –)	10/14 (71.4%)	11/30 (36.7%)	$\chi^2 = 4.62$, <i>P</i> = 0.031
AHR expression			
<i>AHR/β-actin</i> mRNA (<i>n</i>)	0.01 ± 0.02 (4)	0.02 ± 0.03 (16)	NS
AHR score (N-mAb) (–; ±; +)	10;2;0	15;12;2	NS
Detectable AHR (N-mAb) (+/–, +)	2/12 (16.7%)	14/29 (48.3%)	$\chi^2 = 3.56$, <i>P</i> = 0.059
Nuclear AHR (C-pAb)	0/7	2/13	NS

Groups A and B refer to patients and tumours with or without documented *AIP* mutations respectively. *AIP/β-actin* and *AHR/β-actin* mRNA ratios were obtained by real-time RT-PCR (the number of studied tumours is indicated in italicized text within brackets). Semi-quantitative AIP and AHR scores were defined by immunohistochemistry (++ diffuse, strong; + diffuse, moderate; +/- weak immunostaining and/or scattered positive cells; – negative), using anti-AIP and AHR (N-mAb) monoclonal antibodies and, in a subset of cases, a polyclonal anti-AHR antibody (C-pAb) recognizing the C-terminal half of AHR respectively. Nearly significant *P* values are indicated in italics; NS, non-significant.

detectable (scores +/- and +) versus undetectable AHR immunostaining respectively. The level of significance was set at *P* < 0.05.

Results

Normal pituitary

AIP and *AHR* transcripts were detected in normal pituitary samples, with a significantly lower expression of *AHR* (*P* < 0.0001 versus *AIP*). Accordingly, AIP-immunopositive cells were largely present in the adenohypophysis (see Supplementary Fig. 1A, which can be viewed online at <http://erc.endocrinology-journals.org/supplemental/>), with topographical studies arguing for a preferential strong and diffuse expression in somatotrophs (see Supplementary Fig. 1B), and to a lesser extent by lactotrophs (data not shown). AHR (N-mAb) immunostaining was less intense, with a roughly similar, although more scattered and diffuse, cell distribution (see Supplementary Fig. 1C). AIP and AHR (N-mAb) immunostaining was confined to the cytoplasm (see Supplementary Fig. 1D and E), although some degree of AHR nuclear positivity was revealed by C-pAb immunostaining (see Supplementary Fig. 1F). Some scattered AIP- and AHR-immunopositive cells were observed in the *pars intermedia*, containing

ACTH-secreting cells (see Supplementary Fig. 1G–I). Double immunostaining with AHR C-pAb revealed co-localization of AHR with AIP (see Supplementary Fig. 1J), nuclear AHR immunostaining being observed in a subset of somatotrophs (see Supplementary Fig. 1K) and a few corticotrophs (data not shown), whereas in lactotrophs, AHR appeared to be mostly perinuclear (see Supplementary Fig. 1L). FSH-secreting cells were virtually negative for nuclear AHR (data not shown).

Pituitary adenomas

The expression of AIP and AHR has been first performed on the entire series of PA. *AIP* and *AHR* transcripts were detected in all PA (Fig. 1), with a markedly lower AHR expression (*P* < 0.0001 versus *AIP*). Accordingly, AIP and AHR proteins were detected in 84.0 and 38.6% of the cases respectively. Marked individual variations were observed in *AIP* gene expression and immunostaining (Fig. 1A; Table 1) – examples of IHC scoring are shown in Fig. 2A–C, including one microprolactinoma with a normal pituitary fragment shown as an internal control (Fig. 2D). The AIP immunostaining score was significantly correlated with AIP expression (*P* = 0.0014) and with the AHR (N-mAb) score ($\chi^2 = 18.1$, *P* = 0.006). However, cytoplasmic AHR




Figure 3 AIP and AHR immunostaining in *AIP*^{mut} pituitary adenomas. Examples of AIP and AHR immunostaining and relative semi-quantitative AIP evaluation in *AIP*^{mut} PA with references to Table 2 for case identification. (A) AIP immunostaining in a familial somatotrophinoma (Fam 1A) with a R304X mutation (+/–, an area displaying scattered positive cells), with no detectable AHR in the cytoplasm (B) or in the nucleus (C). (D) AIP immunostaining (+) in a familial somatotrophinoma (Fam 4) with an E174fsX21 mutation. (E) Low AIP immunostaining (+/–) and (F) lack of detectable AHR immunostaining in a sporadic somatotrophinoma with a germline A277P mutation (Spor2). (G) Negative AIP immunostaining in a sporadic somatotrophinoma with a Q82fsX7 mutation. Differential expression of AIP in two siblings (Fam 3) with a K241E mutation, affected by a prolactinoma (H) (quoted –) and a NS adenoma (I) (quoted +) respectively.

immunostaining (N-mAb) was generally weak, and nuclear immunostaining (C-pAb) was observed in a minority of cases (12/61 = 19.7%; Fig. 2E–I), including a familial NS PA with normal AIP sequencing (Fig. 2I).

Correlation with clinical characteristics

A series of factors were found to account for the variations in *AIP* mRNA and AIP immunostaining observed on the entire series of PA, including tumour phenotype and aggressiveness (Table 1). Briefly, both were found to be highly variable in somatotrophinomas, generally low in prolactinomas and in other secreting PA, but paradoxically high in a subset of NS adenomas (Fig. 1A; Table 1). *AIP* mRNA was significantly lower in invasive PA ($P=0.0197$ versus non-invasive), which were also more likely to show a low AIP immunostaining ($\chi^2=6.91$, $P=0.009$ versus non-invasive). Overall, no significant difference in AIP expression was observed according to the *AIP* gene status (data not shown). *AHR* mRNA was poorly

influenced by phenotype (Fig. 1B), but complete loss of AHR immunostaining (N-mAb) was significantly more frequent in invasive (71.4 vs 47.4% in non-invasive, $\chi^2=5.2$, $P=0.022$) and in *AIP*^{mut} PA (86.7 vs 58.7% in non-mutated PA, $\chi^2=3.92$, $P=0.048$). Nuclear AHR immunostaining (C-pAb) was observed in three somatotrophinomas, three prolactinomas and six NS adenomas respectively, but in none of the *AIP*^{mut} PA included in this study.

Analysis of PA subgroups

Because the proportion of *AIP*^{mut} tumours varied according to phenotype, data obtained in all somatotrophinomas, prolactinomas and NS adenomas have been further analysed as distinct subgroups.

Somatotrophinomas

As most *AIP*^{mut} tumours were somatotrophinomas, data were analysed according to the presence (group A) or the absence (group B) of documented *AIP* mutations

respectively. In group A, *AIP* mutations were identified on patient's leukocyte DNA in six FIPA patients (eight PA) and in five sporadic cases, respectively, and on tumour cDNA and DNA in an additional sporadic case where no leukocyte DNA was available. Individual data are shown in Table 2 (Family 1, 2 and 4; Spor 2–6 and 8). Germline mutations were heterozygous whereas only the mutated allele was detected in cDNA/tDNA where available, thereby indicating somatic loss of heterozygosity in four out of five cases (Fam 1B and C, Fam 2B; Spor 2) and strongly suggesting hemizyosity in the other case (Spor 8). In group B, the lack of detectable *AIP* mutations was confirmed in most cases by sequencing of gDNA ($n=7$), tumour cDNA ($n=12$) and/or tDNA ($n=4$) respectively. Data observed in group A and group B are summarized in Table 3. Somatotrophinomas occurred in group A at a significantly younger age ($P<0.0001$) were more frequently invasive ($P=0.034$) and more likely to display decreased *AIP* immunostaining ($P=0.031$) than those in group B respectively. Of note, the pattern of *AIP* immunostaining could differ according to the mutation (Fig. 3A, D, E and G). Similarly, there was a trend towards cytoplasmic AHR (N-mAb) being less likely to be detected in group A (Fig. 3B and F) than in group B ($P=0.059$). Further evaluation with the AHR C-pAb confirmed the lack of nuclear immunostaining in group A (Fig. 3C).

Excluding somatotrophinomas with undetermined *AIP* gene status, *AIP* mutations were estimated to account for *AIP* gene down-regulation in 3 out of 4 cases and for low *AIP* immunostaining in 10 out of 19 cases respectively. Low *AIP* immunostaining tended to be more frequent in *AIP*^{mut} somatotrophinomas than in those with normal *AIP* sequencing (10 out of 14 vs 9 out of 22, $\chi^2=3.20$, $P=0.074$), indicating a sensitivity of IHC in detecting *AIP* mutations of 71.4% and a specificity of 40.9% respectively. According to logistic regression analysis, tumour invasiveness was the only independent predictor of *AIP* down-regulation in somatotrophinomas ($P=0.019$), whereas young age was the only independent predictor of *AIP* mutations ($P=0.002$; see Supplementary Table 2, which can be viewed online at <http://erc.endocrinology-journals.org/supplemental/>). Complete loss of AHR (N-mAb) immunostaining was significantly more frequent in invasive than in non-invasive somatotrophinomas (78.9 vs 35.7%, $\chi^2=4.7$, $P=0.012$), while a trend was confirmed in *AIP*^{mut} somatotrophinomas as compared with those with normal *AIP* sequencing (83.3 vs 52.4%, $\chi^2=2.76$, $P=0.096$).

Prolactinomas

Both *AIP* mRNA and *AIP* immunostaining were generally low in prolactinomas (Table 1; Figs 1 and 2C and E). The *AIP* gene status was available in most cases (15 out of 22), according to *AIP* sequencing performed on gDNA ($n=8$) or tumour cDNA ($n=7$). Germline *AIP* mutations were identified in three cases (Table 2, Fam 3B; Spor 1 and 7), although no splicing alteration was found by tumour cDNA sequencing in Spor 7. Low *AIP* immunostaining occurred in prolactinomas with normal *AIP* sequencing (10 out of 12) as well as in *AIP*^{mut} (2 out of 3). Excluding *AIP*^{mut} tumours, low *AIP* immunostaining was confirmed to be significantly more frequent in prolactinomas than in somatotrophinomas ($\chi^2=16.5$, $P=0.0009$). Cytoplasmic (N-mAb) and nuclear (C-pAb) AHR immunostaining could be detected in 11 out of 21 (52.3%) and 3 out of 17 (17.6%) prolactinomas respectively.

NS adenomas

The mean *AIP* mRNA in NS adenomas was similar to that observed in somatotrophinomas, 42.3% of PA in this group also displaying significant *AIP* immunostaining (Table 1; Figs 1 and 2B). A germline *AIP* mutation was identified in one FIPA patient (Table 2, Fam 3A), and normal *AIP* sequencing was documented in 11 cases on tumour cDNA ($n=8$) or tDNA ($n=3$) – including all NS occurring in patients aged ≤ 50 years old. Surprisingly, a significant *AIP* immunostaining was observed in the *AIP*^{mut} NS adenoma (Fig. 3I), but not in the prolactinoma that was surgically resected in her brother (Fig. 3H). *AIP* immunostaining was frequently associated with nuclear AHR (55.5 vs 9.0% according to the presence or the absence of significant *AIP* respectively, $\chi^2=5.09$, $P=0.02$), which in turn was significantly correlated with cytoplasmic AHR ($\chi^2=11.6$, $P=0.0007$). No significant correlation was found between *AIP* and AHR immunostaining and tumour volume, invasiveness or immunostaining for gonadotrophins.

Discussion

This study shows for the first time that both AHR and *AIP* are expressed in the normal human pituitary and frequently down-regulated in PA. In normal pituitaries, topographical studies indicated a preferential expression of *AIP* by somatotrophs, which display a strong and diffuse expression, and to a lesser extent by lactotrophs. These findings are in agreement with recent work by Leontiou *et al.* (2008), which also localized *AIP* within GH and PRL-containing

secretory granules in normal cells. Scattered AIP-expressing cells were also observed in the *pars intermedia*. AHR was expressed at lower transcriptional levels and with a lower immunostaining intensity than AIP, with scattered AHR-expressing cells being more widely distributed than AIP-expressing cells. AIP and AHR were first observed in the cytoplasm only. However, further evaluation with an antibody directed against the C-terminal part of the AHR protein revealed moderate nuclear immunostaining in a subset of somatotrophs and in some corticotrophs. Differences between cytoplasmic and nuclear staining may reflect variations in protein–protein interactions involving AHR in subcellular compartments, which may in turn influence epitope recognition and modify the sensitivity of the corresponding IHC assays. As DNA binding and basic-helix-loop-helix (bHLH)-interacting domains of AHR are located N-terminal (Fukunaga *et al.* 1995, Fukunaga & Hankinson 1996), the N-mAb epitope of AHR may be masqueraded in its transcriptionally active conformation. Thus, nuclear immunostaining with the C-terminal antibody alone may indicate some degree of endogenous AHR activity. Supporting a role for AHR in pituitary development and/or cell differentiation, binding sites for the pituitary transcription factors Lhx3 and Pit-1 are present in the promoter of the *AHR* gene (Harper *et al.* 2006). Constitutive expression of AHR and ARNT has been shown in the rat hypothalamus (Korkalainen *et al.* 2005). These data suggest a physiological role for AHR in the human hypothalamus–pituitary unit, further extending the spectrum of bHLH transcription factors expressed in the normal pituitary and PA (Jackson *et al.* 1993, Ferretti *et al.* 2001, Huang *et al.* 2002, Fratticci *et al.* 2007).

In agreement with a recent report (Leontiou *et al.* 2008), AIP was found by real-time RT-PCR to be expressed at a transcriptional level in all PA, with a relative overexpression in a subset of somatotrophinomas and NS adenomas. Accordingly, significant AIP immunostaining was observed in about half of somatotrophinomas and NS adenomas, but in $\leq 15\%$ of other PA. Thus, AIP expression can be either retained or down-regulated in somatotrophinomas and is frequently decreased in prolactinomas, whereas abnormal AIP expression may occur in a subset of NS adenomas.

We first focused our attention on the significance of AIP down-regulation in somatotrophinomas. In these tumours, decreased gene and protein expression of AIP were significantly associated with the presence of aggressive features and, although AIP immunostaining tended to be lower in *AIP*^{mut} somatotrophinomas, only

invasiveness was an independent predictor of AIP loss. On the other hand, young age (<30 years of age) was an independent predictor for the presence of *AIP* mutations, but not for low AIP immunostaining. These findings may have interesting pathogenetic and clinical implications. First, they strongly suggest that AIP down-regulation may be involved in the progression of somatotrophinomas, regardless of detectable germline *AIP* mutations. Although we cannot exclude the presence of large *AIP* genomic deletions, this is unfrequent (Georgitsi *et al.* 2008b), and additional mechanisms of *AIP* silencing may be present. Second, such data contrast with those obtained in prolactinomas, where a low AIP expression could be observed at early stages of the disease, suggesting a peculiar role for AIP in somatotrophs. This could explain the large predominance of somatotrophinomas among PA developing in patients with germline *AIP* mutations, as reported in this and other studies (Cazabat *et al.* 2007, Daly *et al.* 2007), and the frequent aggressiveness of *AIP*^{mut} somatotrophinomas (Daly *et al.* 2007, Iwata *et al.* 2007, Toledo *et al.* 2007, this study). This is consistent with the high expression of AIP in normal somatotrophs, and supported by functional experiments on GH₃ cells (Leontiou *et al.* 2008). Third, IHC may not be as suitable as previously suggested for the pre-screening of patients with germline *AIP* mutations (Georgitsi *et al.* 2007). Indeed, our data support recent evidence that AIP can frequently be detected in *AIP*^{mut} tumours (Leontiou *et al.* 2008). Such discrepancies may depend on the type of mutation and, to a lesser extent, antibody characteristics. Due to somatic hemizygosity for the mutated *AIP* allele, as further supported by cDNA sequencing in this study, IHC data will depend on epitope expression by the mutated protein, if actually transcribed. In fact, AIP immunostaining can theoretically be retained unless early stop mutations are present. Early data on IHC were obtained in series where Finnish patients and their distinctive Q14X early stop mutation were largely represented (Georgitsi *et al.* 2007). Although the AIP immunoscore in *AIP*^{mut} somatotrophinomas can also be low due to mono-allelic gene expression, this is of limited diagnostic interest, since semi-quantitative interpretation of IHC is difficult to standardize and can be confounded readily. Thus, evidence of AIP immunostaining should not discourage *AIP* gene sequencing in acromegalics with a familial history of FIPA or a young age at disease onset. Furthermore, IHC is unsuitable as a pre-screening tool in prolactinomas, due to the frequent loss of significant AIP immunostaining in this group.

The familial AIP mutations reported herein (E174fs, K241E, Q285fs and R304X) were previously published (Daly et al. 2007, Naves et al. 2007), whereas seven out of the eight nucleotide changes identified in patients with sporadic PA were undescribed. They consisted of one frameshift (Q82fs) and three missense (R128H, V195A and A277P) mutations respectively, three intronic changes (IVS2 c.279+23C>T, IVS3 c.468+16G>T and IVS3 c.468+15C>T) being also recognized. None was observed in controls and comparison with available SNPs, and orthologue sequences' databases were performed (see the electronic Supplementary Materials and methods). Briefly, the Q82fs frameshift mutation is expected to encode for a truncated protein after seven amino acids. None of the novel missense changes has been identified as a SNP to date, the amino acid residues K(241), V(195) and A(277) are highly conserved among species, and loss of the wild-type allele could be verified by cDNA sequencing in the latter case. In contrast, the presence of an arginine or a histidine at position 128 variant occurs variably across mammalian species and may represent an unrecognized human polymorphism, which might explain normal AIP immunostaining in this case. However, the exclusion of this case from *AIP*^{mut} somatotrophinomas did not significantly alter the statistical results obtained in this group (data not shown). Of note, in the siblings affected by a K241E mutation, AIP immunostaining was present in the NS PA, but absent in the prolactinoma. This may reflect the differential AIP expression in these two phenotypes, regardless of the *AIP* mutation itself, which should not affect the epitope recognized by the mAb used in this study. The novel intronic changes, none of them being encountered in controls, are not expected to induce alterations in *AIP* splicing by *in silico* analysis, and this was confirmed by cDNA sequencing in the prolactinoma associated with a germline change in intron 2. However, the contiguity of the two nucleotide changes in intron 3 and the young age of the affected patients, both with somatotrophinomas with a low or heterogeneous AIP immunostaining, favour their possible role in the onset of the disease and suggest possible molecular implications of intronic changes outside recognized splicing sites (Kleinjan & van Heiningen 2005). The R304X mutation was identified in an additional sporadic somatotrophinoma – a young Italian patient unrelated to the family included in this study, which was previously reported in detail (Ferretti et al. 2001, Daly et al. 2007). This mutation has been recurrently recognized in Europe (Vierimaa et al. 2006, Cazabat et al. 2007, Daly et al. 2007, Leontiou et al. 2008), and R304Q mutations being occasionally

reported also (Georgitsi et al. 2007, Leontiou et al. 2008). This reinforces the concept of codon 304 as a relative 'hot spot' in the *AIP* gene, although some founder effect concerning the R304X mutation cannot be excluded. Of note, AIP was detected by IHC in all R304X somatotrophinomas studied so far and, where available, electron microscopy showed sparsely granulated somatotrophinomas (Ferretti et al. 2001, Leontiou et al. 2008).

Another major aim of this study was to investigate for the first time the possible role of AHR in the pathogenesis of PA, especially in *AIP*^{mut} tumours. Low levels of *AHR* transcripts were found in PA as well as in normal pituitary samples. Cytoplasmic AHR immunostaining was detected in 40.0% of PA, being generally weaker in intensity as compared with normal pituitaries, and significantly correlated with AIP immunostaining. This is consistent with AHR destabilization in the presence of low AIP levels, thereby supporting a role for AIP in AHR cytoplasmic stabilization in the human pituitary, as observed in most tissues. In *AIP*^{mut} PA, AHR can be further destabilized by a defective interaction with the AIP protein. As the C-terminal half of AIP is critical for interaction with AHR, which is abolished by truncation of the last five amino acids (Bell & Poland 2000), *AIP*-truncating mutations are expected to prevent the constitution of the cytoplasmic complex. The functional implications of each missense mutation would need specific *in vitro* experiments, but a number of single amino acid changes occurring in the TPR region can abolish AIP binding to hsp90 and/or strongly reduce AIP/AHR interaction (Bell & Poland 2000, Petrusis & Perdew 2002). The N-terminal part of AIP may also contribute to the cytoplasmic stabilization of AHR (Kazlauskas et al. 2002). Accordingly, none of the *AIP*^{mut} PA showed nuclear AHR staining, suggesting that increased AHR nuclear signalling is not implicated in AIP-related tumorigenesis. Hence, AHR down-regulation may be involved in *AIP*^{mut} and/or invasive somatotrophinomas, although we cannot exclude a non-specific bystander effect of AIP down-regulation. In contrast, AHR appears to be up-regulated in a subset of NS overexpressing AIP. Of note, NS but not GH-secreting PA have been reported after Seveso's exposure (Pesatori et al. 2008). These findings suggest a differential role of AHR in pituitary cells, and further *in vitro* investigations should help clarifying these issues.

In addition to AHR modulation, AIP is known to interact with a number of cytoplasmic proteins including phosphodiesterases (Bolger et al. 2003, de Oliveira et al. 2007), thereby possibly modulating

cAMP concentration, survivin, an anti-apoptotic protein (Kang & Altieri 2006), and Ret (Vargiolu *et al.* 2009). Interactions with phosphodiesterases can be altered by AIP mutations (Bolger *et al.* 2003, de Oliveira *et al.* 2007). Possible alterations in cAMP signalling or apoptosis accompanying down-regulation of AIP in somatotrophinomas or increased AIP expression in NS PA should be further investigated.

In conclusion, this study supports the role of AIP in the cytoplasmic stabilization of AHR and shows that reduced AIP and AHR expression are frequently observed in PA, at least at a protein level, with the exception of NS adenomas, in which up-regulation of both proteins can be observed. It suggests a possible role for AIP and AHR down-regulation in the progression of somatotrophinomas, independently from germline mutations, and indicates that IHC is not a sufficiently sensitive tool for the detection of AIP mutations in somatotrophinomas, and is unsuitable to this purpose in prolactinomas or NS PA.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was partially supported by grants from the Italian Ministry for University and Research (MIUR), Neuromed Institute, IRCCS, and the ‘Carlo Ferri’ Foundation for the prevention in oncology, Italy, and by the Fonds d’Investissement pour la Recherche Scientifique 2007 (FIRS) du CHU de Liège, Belgium.

Acknowledgements

The authors wish to thank Maria-Antonietta Oliva and Dr Remo Bernabei for their excellent technical assistance, Pr Luiz Augusto Casulari and Dr Maria Yaneva for their contribution to patients’ follow-up.

References

Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, Tamagno G, Cazabat L, Bours V, Brue T *et al.* 2007 Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism* **92** 1952–1955.

Barouki R, Coumoul X & Fernandez-Salguero P 2007 The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. *FEBS Letters* **581** 3608–3615.

Beckers A & Daly AF 2007 The clinical, pathological, and genetic features of familial isolated pituitary adenomas. *European Journal of Endocrinology* **157** 371–382.

Bell DR & Poland A 2000 Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. *Journal of Biological Chemistry* **275** 36407–36414.

Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS & Houslay MD 2003 Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. *Journal of Biological Chemistry* **278** 33351–33363.

Buchbinder S, Bierhaus A, Zorn M, Nawroth PP, Humpert P & Schilling T 2008 Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas. *Experimental and Clinical Endocrinology & Diabetes* **116** 625–628.

Cazabat L, Libè R, Perlemoine K, René-Corail F, Burnichon N, Gimenez-Roqueplo AP, Dupasquier-Fediaevsky L, Bertagna X, Clauser E, Chanson P *et al.* 2007 Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. *European Journal of Endocrinology* **157** 1–8.

Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T *et al.* 2006 Clinical characterization of familial isolated pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism* **91** 3316–3323.

Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G *et al.* 2007 Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. *Journal of Clinical Endocrinology and Metabolism* **92** 1891–1896.

Elango A, Shepherd B & Chen TT 2006 Effects of endocrine disruptors on the expression of growth hormone and prolactin mRNA in the rainbow trout pituitary. *General and Comparative Endocrinology* **145** 116–127.

Ferretti E, Jaffrain-Rea ML, Asteria C, Di Stefano D, Esposito V, Ferrante L, Daniele P, Tiberti C, Gallucci M, Bosman C *et al.* 2001 Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic features. *European Journal of Endocrinology* **144** 227–235.

Fratricci A, Grieco FA, Spilioti C, Giangaspero F, Ventura L, Esposito V, Piccirilli M, Santoro A, Gulino A, Cantore G *et al.* 2007 Differential expression of neurogenins and NeuroD1 in human pituitary tumours. *Journal of Endocrinology* **194** 475–484.

Fukunaga BN & Hankinson O 1996 Identification of a novel domain in the aryl hydrocarbon receptor required for DNA binding. *Journal of Biological Chemistry* **271** 3743–3749.

- Fukunaga BN, Probst MR, Reisz-Porszasz S & Hankinson O 1995 Identification of functional domains of the aryl hydrocarbon receptor. *Journal of Biological Chemistry* **270** 29270–29278.
- Gasiewicz TA, Henry EC & Collins LL 2008 Expression and activity of aryl hydrocarbon receptors in development and cancer. *Critical Reviews in Eukaryotic Gene Expression* **18** 279–321.
- Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Mäkinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T et al. 2007 Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. *PNAS* **104** 4101–4105.
- Georgitsi M, De Menis E, Cannavò S, Mäkinen MJ, Tuppurainen K, Pauletto P, Curtò L, Weil RJ, Paschke R, Zielinski G et al. 2008a Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. *Clinical Endocrinology* **69** 621–627.
- Georgitsi M, Heliövaara E, Paschke R, Kumar AV, Tischkowitz M, Vierimaa O, Salmela P, Sane T, De Menis E, Cannavò S et al. 2008b Large genomic deletions of aryl hydrocarbon receptor interacting protein (AIP) gene in pituitary adenoma predisposition. *Journal of Clinical Endocrinology and Metabolism* **93** 4146–4151.
- Harper PA, Riddick DS & Okey AB 2006 Regulating the key regulator: factors that control levels and activity of the aryl hydrocarbon receptor. *Biochemical Pharmacology* **72** 267–279.
- Huang P, Ceccatelli S, Håkansson H, Grandison L & Rannug A 2002 Constitutive and TCDD-induced expression of Ah receptor-responsive genes in the pituitary. *Neurotoxicology* **23** 783–793.
- Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T & Yoshimoto K 2007 The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. *Clinical Endocrinology* **66** 499–502.
- Jackson SM, Barnhart KM, Mellon PL, Gutierrez-Hartmann A & Hoffer JP 1993 Helix-loop-helix proteins are present and differentially expressed in different cell lines from the anterior pituitary. *Molecular and Cellular Endocrinology* **96** 167–176.
- Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A & Cantore G 2002 A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. *Endocrine-Related Cancer* **9** 103–113.
- Kang BH & Altieri DC 2006 Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. *Journal of Biological Chemistry* **281** 24721–24727.
- Kazlauskas A, Poellinger L & Pongratz I 2002 Two distinct regions of the immunophilin-like protein XAP2 regulate dioxin receptor function and interaction with hsp90. *Journal of Biological Chemistry* **277** 11795–11801.
- Kleinjan DA & van Heiningen V 2005 Long-range control of gene expression: emerging mechanisms and disruption in disease. *American Journal of Human Genetics* **76** 8–32.
- Korkalainen M, Lindén J, Tuomisto J & Pohjanvirta R 2005 Effect of TCDD on mRNA expression of genes encoding bHLH/PAS proteins in rat hypothalamus. *Toxicology* **208** 1–11.
- LaPres JJ, Glover E, Dunham EE, Bunker MK & Bradfield CA 2000 ARA9 modifies agonist signaling through an increase in cytosolic aryl hydrocarbon receptor. *Journal of Biological Chemistry* **275** 6153–6159.
- Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J et al. 2008 The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism* **93** 2390–2401.
- Marlowe JL & Puga A 2005 Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. *Journal of Cellular Biochemistry* **96** 1174–1184.
- Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C, Magalhães AV, Azevedo MF, Giacomini LA, Nascimento PP, Nunes RO et al. 2007 Variable pathological and clinical features of a large Brazilian family harbouring a mutation in the aryl hydrocarbon receptor-interacting protein gene. *European Journal of Endocrinology* **157** 383–391.
- Nguyen LP & Bradfield CA 2008 The search for endogenous activators of the aryl hydrocarbon receptor. *Chemical Research in Toxicology* **21** 102–116.
- Nishimura N, Miyabara Y, Sato M, Yonemoto J & Tohyama C 2002 Immunohistochemical localization of thyroid stimulating hormone induced by a low oral dose of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in female Sprague–Dawley rats. *Toxicology* **171** 73–82.
- de Oliveira SK, Hoffmeister M, Gambaryan S, Müller-Esterl W, Guimaraes JA & Smolenski AP 2007 Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. *Journal of Biological Chemistry* **282** 13656–13663.
- Pesatori A, Baccarelli A, Consonni D, Lania A, Beck-Peccoz P, Bertazzi P & Spada A 2008 Aryl hydrocarbon receptor interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. *European Journal of Endocrinology* **159** 699–703.
- Petrucci JR & Perdew GH 2002 The role of chaperone proteins in the aryl hydrocarbon receptor core complex. *Chemico-Biological Interactions* **141** 25–40.

- Pitt JA, Buckalew AR, House DE & Abbott BD 2000 Adrenocorticotropin (ACTH) and corticosterone secretion by perfused pituitary and adrenal glands from rodents exposed to 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD). *Toxicology* **151** 25–35.
- Pocar P, Fischer B, Klonisch T & Hombach-Klonisch S 2005 Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. *Reproduction* **129** 379–389.
- Popp JA, Crouch E & McConnell EE 2006 A weight-of-evidence analysis of the cancer dose–response characteristics of 2,3,7,8-tetrachlorodibenzodioxin (TCDD). *Toxicological Sciences* **89** 361–369.
- Schlezinger JJ, Liu D, Farago M, Seldin DC, Belguise K, Sonenshein GE & Sherr DH 2006 A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. *Biological Chemistry* **387** 1175–1187.
- Toledo RA, Lourenço DM Jr, Liberman B, Cunha-Neto MB, Cavalcanti MG, Moyses CB, Toledo SP & Dahia PL 2007 Germline mutation in the aryl hydrocarbon receptor interacting protein gene in familial somatotropinoma. *Journal of Clinical Endocrinology and Metabolism* **92** 1934–1937.
- Vargiolu M, Fusco D, Kurelac I, Dirnberger D, Baumeister R, Morra I, Melcarne A, Rimondini R, Romeo G & Bonora E 2009 The tyrosine kinase receptor RET interacts *in vivo* with AIP to alter survivin availability. *Journal of Clinical Endocrinology and Metabolism* **94** 2571–2578.
- Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R *et al.* 2006 Pituitary adenoma predisposition caused by germline mutations in the AIP gene. *Science* **312** 1228–1230.